Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Tweet Send to a Friend
Laidlaw analyst Yale Jen reiterated a Buy rating and $50.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
